Fator VIII/farmacologia; Hemofilia A/tratamento farmacológico; Animais; Fatores de Coagulação Sanguínea/metabolismo; Fator VIII/efeitos adversos; Feminino; Hemofilia A/sangue; Hemostasia; Humanos; Masculino; Camundongos; Camundongos Knockout; Coelhos; Distribuição Aleatória; Proteínas Recombinantes/efeitos adversos; Proteínas Recombinantes/farmacologia

ADA; AUC; AUC from 0 to 24hours; AUC from 0 to last timepoint; AUC(0-last); AUC(0­24h); B-domain deleted; BDD; C(max); CFT; CHO; CI; CT; Chinese hamster ovary; ELISA; ETP; FVIII; GLP; PTF; TGA; VWF; aPCC; aPTT; activated partial thromboplastin time; activated prothrombin complex concentrate; activated recombinant factor VIII; anti-drug antibody; area under the curve; clot formation time; clotting time; confidence interval; endogenous thrombin potential; enzyme-linked immunosorbent assay; factor VIII; good laboratory practice; half-life; hemostasis; maximum concentration; potentiation of thrombus formation; preclinical; rFVIII; rFVIIIa; rVIII-SingleChain; recombinant; recombinant factor VIII; t(1/2); t(max); thrombin generation assay; time taken to achieve C(max); von Willebrand factor